Early Medidata backer plans $150M digital-health fund

Milestone Venture Partners is readying a digital-health investment fund. The VC shop is aiming to raise $150 million from biopharma companies and others to invest in up to 20 early-stage digital health companies.

The new fund marks a slight shift in approach. New York, NY-based Milestone has a history of backing digital health companies--it has invested in 17 and exited eight--but the new fund will focus solely on the niche, VentureWire reports. The sector has proved profitable for Milestone, which invested in Medidata ($MDSO) when it was still a privately-held eClinical startup. When Milestone distributed Medidata shares for $7.65 each in 2009, it resulted in a 34 times return on its initial investment.

Medidata now trades at $44 a share and the overall digital health market has grown, too. Milestone thinks that by focusing on the hot niche--in which it has a proven track record--it can make a simpler pitch to investors. The VC shop is in the middle of raising $150 million for the digital-health fund--its fifth overall--and is approaching a broad range of potential backers. Strategic investors such as drug manufacturers are being targeted, as are the financiers that supported Milestone's other funds.

Milestone plans to allocate the $150 million to 15 to 20 early-stage digital health companies, specifically businesses that are just starting to introduce a product and generate sales. This stage can prove tricky for digital health companies. Multiple investment groups are interested in making fairly small seed investments in very early-stage startups, but fewer are willing to cough up the larger sums needed to help companies make the final leap toward being a financially-sustainable business.

- read VentureWire's article

Suggested Articles

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

Eric Perakslis' experience with Takeda will help facilitate a new collaboration between the two companies.

The $58 million financing round represents biopharma industry's growing interest in genomics data.